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Abstract. Magnetic Resonance Spectroscopic Imaging (MRSI) is a clin-
ical imaging modality for measuring tissue metabolite levels in-vivo. An
accurate estimation of spectral parameters allows for better assessment
of spectral quality and metabolite concentration levels. The current gold
standard quantification method is the LCModel - a commercial fitting
tool. However, this fails for spectra having poor signal-to-noise ratio
(SNR) or a large number of artifacts. This paper introduces a frame-
work based on random forest regression for accurate estimation of the
output parameters of a model based analysis of MR spectroscopy data.
The goal of our proposed framework is to learn the spectral features
from a training set comprising of different variations of both simulated
and in-vivo brain spectra and then use this learning for the subsequent
metabolite quantification. Experiments involve training and testing on
simulated and in-vivo human brain spectra. We estimate parameters such
as concentration of metabolites and compare our results with that from
the LCModel.
1 Introduction
Magnetic resonance spectroscopic imaging (MRSI) is an in-vivo clinical imaging
modality which detects nuclear magnetic resonance signals produced by nuclei in
living tissues. Quantification of this signal amplitude generates metabolic maps
which show the concentration of metabolites in the sample being investigated.
Accurate quantification of these metabolites is important for diagnosis of brain
tumor and other in-vivo diseases. For this purpose, a common practice in the
MRS community has been to use non-linear spectral fitting tools such as the
LCModel [5], TARQUIN [9], AMARES [8] and ProFit [7] amongst which the
LCModel is regarded as the gold standard fitting tool. In this study, we present
an alternative to the non-linear model fitting using a machine learning approach.
Non-linear model fitting. The LCModel software uses a linear combina-
tion of metabolite basis spectra set to model the spectral measurement in the
frequency domain. It also uses smoothing splines to model the baseline signals
and subsequently fits the parameters of the basis set using a non-linear optimisa-
tion. LCModel incorporates the prior knowledge of the data while modeling the
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fit and this ensures robustness in the model leading to estimation of the spec-
tral parameters such as concentration of metabolites. Some of the drawbacks
of this non-linear fitting model are: (1) Metabolite quantification can be time-
consuming depending on the dataset size and requires a lot of manual parameter
tuning. (2) The error in estimating parameters is lower if high SNR spectra are
used since the non-linear voxel-wise fitting to noisy data leads to a high amount
of local minima and subsequent inaccuracy in quantification. [4][3].
Machine Learning. Machine learning methods such as decision forests,
random forests [2] are being extensively used in the medical imaging community
for tasks such as parameter estimation, diseases diagnosis, segmentation, etc.
In MRSI, machine learning tools have been used only for specific tasks such as
classification of spectra [4] and assessment of spectral quality [1]. This opens up
the possibility of using the recent advances in machine learning to predict MRSI
data parameters while addressing the drawbacks of conventional fitting tools
such as long computation time and poor performance for data with artifacts.
Our Contribution. In this work, we propose a simple yet effective method
using random forest regression for multi-parameter estimation in MR Spectro-
scopic Imaging. We generate over 1 million simulated spectra training-set having
concentration magnitudes, linewidth effects, baseline and lipid artifacts. We also
use spectral data from 287 human subjects to create a physical training model to
be used in the regression framework (Sect. 3.1). In the following we present our
method adapting random forest regression to MRSI (Sect. 2) followed by exper-
iments in the aforementioned dataset. Our proposed method is then validated
quantitatively and qualitatively using: (1) synthetic brain spectra, (2) human
in-vivo single voxel spectra having the same image acquisition protocol as the
physical training model and (3) independently acquired human in-vivo 2D MRS
Images to perform a blind test on the physical and synthetic models. We present
the results (Sect. 3.2) of our experiments followed by a summary and discussion
(Sect. 4) on the future work in this domain. This is the first application- to the
best of our knowledge- of machine learning for determining MRS parameters
which were otherwise determined using basis fitting tools.
2 Methods
MR Spectroscopy. Magnetic resonance spectroscopy, based on the concept
of nuclear magnetic resonance (NMR), exploits the resonance frequency of a
molecule, to obtain information about the concentration of a particular metabo-
lite [6]. The time-domain complex signal of a nuclei is given by:
S(t) =
∫
p(ω)exp(−iΦ)exp(−t/T ∗2 )dw. (1)
The frequency-domain signal is given by S(ω), T ∗2 is the magnetization decay in
the transverse plane due to magnetic field inhomogeneity and p(ω) comprises of
Lorentzian absorption and dispersion line-shapes function having the spectro-
scopic information about the sample. Φ represents the phase, (ωt + ω0), of the
acquired signal where ωt is the time-varying phase change and ω0 is the initial
phase. Non-linear fitting tools facilitate the generation of metabolic maps to es-
timate concentration of metabolites such as N-acetyl-aspartate (NAA), Creatine
(Cr) and Choline (Cho). An example of the spectra present in the brain has been
shown in Fig. 1.
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Fig. 1. Example brain 2D MRSI dataset. (A) The simulated brain with the region of
interest (red box). (B) Highlighted regions corresponding to GM, WM and CSF (c)
Corresponding spectrum of GM, WM and CSF.
Random Forest Regression. Random Forests [2] have been shown to be
effective in a wide range of classification and regression problems. These comprise
of a set of binary trees wherein splits are created in each tree based on a random
subsets of the feature variables on which the forests are subsequently trained.
Piecewise linear regression is implemented by each tree over the input data and,
after seeking for the best prediction at every node, data points are sent to the
left or right branches based on feature selection by thresholding. This process
continues till it reaches the end of the tree and subsequently the weighted average
of the prediction from each tree is taken to give a single output estimate. The
randomness in the training process encourages the trees to give independent
estimates which can be combined to achieve an accurate and robust result.
For MRSI, we adapt the random forest approach to have a training dataset
D = (Si(ω), Yi) , i ∈ [1, N ], where N is the total number of training spectra.
Si(ω) represents the training spectral data while Yi represents the corresponding
multi-parameter training labels. For our model, we consider the concentrations
of NAA, Cho and Cr for simulated data, while for the real data we additionally
consider Myo-Inositol (mI) and Glutamate+Glutamine (Glx). Therefore, for a
given spectra Si(ω), Yi = [ NAAi, Choi, Cri, mIi, Glxi ].
Running the random forest regression on this produces a training model
which can then be used to obtain parameter estimates Yˆj of test spectra Sj(ω)
having test labels Yj , j ∈ [1,M ] where M is the total number of test spectra.
Error Calculation. For our experiments, given the estimate Yˆj and the
testing label Yj , the estimate error for the parameter Yj can be calculated as,
Eˆj = ||Yˆj − Yj ||./||Yj || (2)
This method helps us to assess the change in parameter estimate over the
testing/ground-truth values.
3 Experiments and Results
3.1 Data
We perform 4 sets of experiments to assess our proposed method: (1) training and
testing on simulated spectra (Synthetic - Synthetic (Spectra)), (2) training
and testing on human in-vivo spectral data from different subjects but having
the same acquisition protocol (Real (Spectra) - Real (Spectra)), (3) training
and testing on human in-vivo spectral data from different subjects with different
acquisition protocol (Real (Spectra) - Real (MRS Images)) and (4) using
the simulated spectra model to test on MRS images (Synthetic (Spectra) -
Real (MRS Images)).
Synthetic (Spectra). A metabolite basis set was generated by using the
data provided by the ISMRM MRS Fitting Challenge 2016. These were then
used to simulate over 1 million spectra. In order to ensure that the simulated
spectra was as close as possible to human in-vivo spectra, we incorporate the
following features: variations in NAA, Cho, Cr concentrations, macro-molecular
baseline, lipids, t2 values (for changes in linewidth) and signal-to-noise ratio
(SNR) to account for changes in spectral quality. As a preliminary case study,
we only simulate the major metabolites (NAA, Cho and Cr) as these are easily
detected by the LCModel and would, therefore, help us to evaluate the outcome
of our approach and allow a suitable comparison with the LCModel. A set of over
10,000 independent test spectra were also simulated with varying combinations
of the aforementioned features. For both the training and testing sets, we used
the basis-set metabolite concentration values as our ground-truth.
Real (Spectra). To evaluate our method on in-vivo data, we utilize LCModel-
fitted single-voxel spectroscopy (SVS) data from 287 independent human sub-
jects. The data was obtained using the same standardized imaging protocol with
the following acquisition parameters: TE/TR = 35/2000 ms, spectral width =
2500 Hz, number of points = 1024. We implement a K-fold cross-validation
with 10 folds along with the random-forest regression to generate different train-
ing and testing sets having spectra from 259 and 28 subjects respectively. The
metabolites assessed were: NAA, Cho, mI and Glx.
Real (MRS Images). To further assess our approach, we acquire a standard
phase-encoded 2D brain MRSI data of a healthy human volunteer on a 3T scan-
ner using a point-resolved spin-echo localization sequence (PRESS) with voxel
size = 10x10x15 mm3, TE/TR=35/1000 ms, spectral width = 2000 Hz, number
of points = 400. For testing purposes, we use 96 spectra from the inner-region
of the brain which serves as the region of interest.
Due to the differences in acquisition parameters of the training and testing
set, both the resulting spectra vary in amplitude and metabolite peak alignment.
We perform a pre-processing spectral alignment step where all the test spectra
are cropped from 4.3 to 0.2 ppm and interpolated to the same number of points
as the training spectra to compensate for differences in acquisition bandwidth.
This is followed by normalizing the amplitude of the test spectra using one of
the training spectra as reference.
3.2 Results
Synthetic - Synthetic (Spectra). We perform an initial experiment to deter-
mine the out-of-bag (OOB) error using different number of trees and features on
a set of 20,000 simulated train and test spectra. Based on the results shown in
Fig. 2, we proceed with the parameter estimation experiment by identifying the
appropriate number of trees and features required to achieve convergence of the
OOB error. For the regression error estimates, we use metabolite concentration
ratios with respect to Cr (used as a standard assessment method in MRS as a
means for calibration). We obtain R scores of 0.968 and 0.962 for NAA/Cr and
Cho/Cr values respectively. The corresponding figures representing the linear re-
gression are shown in Fig.3 and the error plots in comparison with the LCModel
are shown in Fig.4.
Fig. 2. Out-Of-Bag (OOB) Er-
ror for Simulated Spectra. The
experiment is performed for a
varying number of features (from
1 to 256 as shown in the legend)
and each iteration is assessed for
a varying number of trees (as
shown in the X-axis). The Y-
axis represents the OOB Error
rate. The error rate is minimal
for more than 64 features and
also converges when the number
of trees is close to 100.
Real (Spectra) - Real (Spectra). For the SVS dataset, we use the LCModel
concentration ratio estimates as the ground-truth. Table.1 indicates the mean
metabolite concentration estimate error across the 10-folds of the cross-validation
process using the random forest regression method. Median error for the NAA/Cr
estimate is 0.068, 0.072 for the Cho/Cr estimate, 0.093 for the mI/Cr estimate
and 0.070 for the Glx/Cr estimate compared to the corresponding LCModel
estimates. The difference in error estimates is small and shows a similarity in
assessment between our proposed method and the LCModel. Moreover, the low-
concentration metabolites such as mI and Glx usually display a fitting error with
the LCModel and the estimation error for these metabolite ratio concentrations
is lower indicating that our model works well for these metabolites as well.
Fig. 3. Regression Scores for the following parameters (from left to right): NAA/Cr
concentration estimate and Cho/Cr concentration estimate. The X-axis represents the
true values of the parameter while the y-axis represents the estimated values. Both sets
of values are plotted using linear regression.
Fig. 4. Synthetic-Synthetic (Spectra): Estimation error for different metabolite
concentration ratios in a given test-set. Whiskers span the [min max] values. Median
error values are represented by the red line and are as follows: NAA/Cr Regression
= 0.064, LCModel = 0.077, Cho/Cr Regression = 0.043, LCModel = 0.070.
Table 1. Concentration-ratio estimate errors using random forest regression. Re-
sults are for the experiments Real(spectra)-Real(spectra) and Real(spectra)-
Real(Images). The errors are calculated over the respective LCModel estimates as
per the formula given in Eq.2. The major metabolites (NAA and Cr) show a low error
while the smaller concentration metabolites (mI and Glx) show a slightly higher error.
Naa/Cr Cho/Cr mI/Cr Glx/Cr
Real-Real (Spectra) 0.068 0.072 0.093 0.070
Real-Real (Images) 0.1 0.18 0.217 0.13
Synthetic (Spectra) - Real (Images). We test our synthetic spectra train-
ing model on the 2D MRSI data and the results are shown in the boxplot in Fig.
5 along with the resulting concentration distribution from both the regression
approach and the non-linear model fit. As our synthetic model is trained for only
NAA and Cho ratios, we show the errors for these two only. Median estimate
Fig. 5. Left: Synthetic (Spectra)-Real (MRS Images): Estimation error for different
metabolite concentration ratios for the same test dataset. Whiskers span the [min max]
values. Median error values are represented by the red line and are as follows: NAA/Cr
= 0.024, Cho/Cr = 0.034. Right: NAA/Cr and Cho/Cr concentration distribution
estimates from random forest regression and non-linear model fit.
error for NAA/Cr is 0.24 using regression. For Cho/Cr, the estimation error
is 0.34. The corresponding concentration values estimated from the LCModel
serves as our ground-truth.
Real (Spectra) - Real (Images). We perform a blind test with 96 2D
MRSI spectra against the training model generated using the 287 SVS spectra
and the results are shown in Table. 1. Median estimate error for NAA/Cr is
0.1, for Cho/Cr is 0.18, for mI/Cr is 0.217 and for Glx/Cr is 0.13. Although we
expect the errors to be higher in the blind test due to difference in the acquisition
protocols of the training and testing dataset, the errors appear to be within a
reasonable window. As expected, the estimated errors are highest for mI/Cr
while Glx/Cr surprisingly has a lower error than Cho/Cr.
The Real Spectra training model provides a marginally better metabolite
concentration estimate than the Synthetic spectra model . We attribute this to
the presence of arbitrary scanning effects and artifacts in the real spectra model
as compared to the synthetic model. For future experiments, this provides the
scope for learning on a large synthetic spectral data-set with similar additional
arbitrary effects to have a robust classifier for real data (especially in the cases
where annotating training data is expensive).
4 Conclusion
Machine learning techniques such as Random Forest-based regression provide a
new and faster way of metabolite quantification. Our synthetic training model
accounts for spectral features such as macro-molecular baseline, lipids, linewidth
and SNR variations in combination with different metabolite concentrations.
Additional features such as frequency and/or phase-shift effects along with B0
inhomogeneity could be incorporated in the model to improve robustness. For
the human in-vivo data, we use training spectra from different subjects and the
random-forest regression provides a low amount of estimation error over the
LCModel fit even in the presence of arbitrary scanning effects. Training times
for the simulated spectra can be considerable (around 5-6 hours) given that we
generate over 1 million spectra while it is only a few minutes for the in-vivo
spectra. On the other hand, testing and concentration estimation happens in
only a few seconds and is considerably faster than the non-linear model fitting.
The machine learning approach may be used directly, or indirectly by initializ-
ing LCModel fits thereby improving their results in the presence of noise and
speeding up convergence. They can also be combined with global decisions about
spectral quality predicting whether a spectrum can or cannot be interpreted by
the physics model because of the presence of artifacts.
Future work would involve using a more robust approach such as deep-
learning based methods to improve the accuracy of parameter estimation. Once
a framework has been established, further work can be done on having disease-
based training models for parameter estimation to predict disease progression
and the corresponding metabolite maps.
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